Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsJaykumar Thumar, MBBS, MD
Adjunct Assistant ProfessorAbout
Copy Link
Titles
Adjunct Assistant Professor
Biography
Dr Thumar completed his residency (Internal Medicine) from Civil Hospital, Ahmedabad, India. During his medical training at Gujarat Cancer Research Institute he developed major interest in medical oncology and basic science research. He served as post doctoral research fellow at Center for Vascular Biology, University of Connecticut. He completed his additional internship and residency training in internal medicine at University of Connecticut, Farmington, CT. He served as Chief Medical Resident at John Dempsey Hospital, Farmington, CT. He then served as a Fellow in Hematology and Oncology at Yale Cancer Center, New Haven, CT.
Appointments
Medical Oncology and Hematology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- Internal Medicine
- Medical Oncology and Hematology
- Yale Cancer Center
Education & Training
- MD
- Yale University, Medical Hematology Oncology (2012)
- Chief Medical Resident
- University of Connecticut (2009)
- MD
- University of Connecticut, Internal Medicine (2008)
- MBBS
- B.J. Medical College (2000)
Research
Copy Link
Research at a Glance
Yale Co-Authors
Publications Timeline
Daniel Zelterman, PhD
Jeremy Kortmansky, MD
Jingjing Jiao
Kevin Billingsley, MD, MBA, FACS
Kimberly L. Johung, MD, PhD
Luisa Escobar-Hoyos, MSc, PhD
Publications
2026
YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination.
Smithy J, Ciallella V, Thant C, Kalvin H, Thumar J, Nair S, Shoushtari A, Momtaz P, Chen M, Panageas K, Greenbaum B, Mohibullah N, Postow M. YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination. Journal Of The National Comprehensive Cancer Network 2026, 24 PMID: 42055072, DOI: 10.6004/jnccn.2025.7450.Peer-Reviewed Original ResearchPP388 A phase 1b dose escalation study of AV-380 (anti-GDF15 monoclonal antibody) in combination with standard-of-care therapy in cancer patients with cachexia
Lee H, Roeland E, Tejani M, Cheung E, Dincman T, Lohiya V, Agarwal R, Sajid S, Gabayan A, Thumar J, Jin B, Lebedinsky C, Braendle E, Zuniga R. PP388 A phase 1b dose escalation study of AV-380 (anti-GDF15 monoclonal antibody) in combination with standard-of-care therapy in cancer patients with cachexia. ESMO Open 2026, 11: 106013. DOI: 10.1016/j.esmoop.2025.106013.Peer-Reviewed Original Research
2025
A phase 1b dose escalation study of AV-380 (anti-GDF15 monoclonal antibody) in combination with standard-of-care therapy in cancer patients with cachexia.
Roeland E, Tejani M, Cheung E, Dincman T, Lohiya V, Agarwal R, Sajid S, Gabayan A, Thumar J, Jin B, Lebedinsky C, Braendle E, Zuniga R. A phase 1b dose escalation study of AV-380 (anti-GDF15 monoclonal antibody) in combination with standard-of-care therapy in cancer patients with cachexia. Journal Of Clinical Oncology 2025, 43: tps12142-tps12142. DOI: 10.1200/jco.2025.43.16_suppl.tps12142.Peer-Reviewed Original ResearchCitationsConceptsGDF-15Multicenter phase 1b studyStandard-of-care therapyProportion to disease severityEscalating dose cohortsDose-limiting toxicityPhase 1b studyDose-escalation studyPathogenesis of cachexiaGDF-15 expressionRisk of side effectsAnti-drug antibodiesHigher risk of deathOff-label treatmentFDA-approved therapiesTreating cancer cachexiaAnimal cancer modelsPhase 1 healthy volunteer studyCirculating GDF-15Body weight regulationReverse weight lossRisk of deathYears of ageIgG1 monoclonal antibodyPatient-reported outcomesOutcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population.
Ganguly A, Paladiya R, Ingawale S, Giri S, Abbagoni V, Thumar J. Outcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population. Journal Of Clinical Oncology 2025, 43: 208-208. DOI: 10.1200/jco.2025.43.4_suppl.208.Peer-Reviewed Original ResearchConceptsTNT groupTotal neoadjuvant therapyLocally Advanced Rectal CancerAdvanced rectal cancerManagement of locally advanced rectal cancerTumor locationNeoadjuvant therapyConventional therapyRectal cancerCT groupPropensity score matchingLow tumorsHigh tumorNo responsePathologic response to treatmentTreating locally advanced rectal cancerResponse ratePartial response ratePathological response rateScore matchingFisher's exact testResponse to treatmentComplete responseAdjuvant treatmentUnderserved populations
2024
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Shroff R, King G, Colby S, Scott A, Borad M, Goff L, Matin K, Mahipal A, Kalyan A, Javle M, Dika I, Tan B, Cheema P, Patel A, Iyer R, Kelley R, Thumar J, El-Khoueiry A, Guthrie K, Chiorean E, Hochster H, Philip P. SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. Journal Of Clinical Oncology 2024, 43: 536-544. PMID: 39671534, PMCID: PMC11798714, DOI: 10.1200/jco-24-01383.Peer-Reviewed Original ResearchCitationsAltmetricConceptsProgression-free survivalBiliary tract cancerAdvanced biliary tract cancerOverall survivalGallbladder carcinomaExtrahepatic cholangiocarcinomaIntrahepatic cholangiocarcinomaHazard ratioNab-paclitaxelMedian progression-free survivalMetastatic biliary tract cancerProgression-free survival benefitPhase III randomized trialGemcitabine-cisplatin regimenTrial of gemcitabineLocally advanced diseaseExploratory subset analysisDiagnosing BTCEvaluated gemcitabineMedian OSMetastatic diseaseAdvanced diseaseNo significant differenceSubset analysisGemcitabinePerioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchCitationsAltmetricConceptsProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled TrialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOX
2010
Differential Protein Expression Profiles in Estrogen Receptor–Positive and –Negative Breast Cancer Tissues Using Label-Free Quantitative Proteomics
Rezaul K, Thumar J, Lundgren D, Eng J, Claffey K, Wilson L, Han D. Differential Protein Expression Profiles in Estrogen Receptor–Positive and –Negative Breast Cancer Tissues Using Label-Free Quantitative Proteomics. Genes & Cancer 2010, 1: 251-271. PMID: 21779449, PMCID: PMC3092194, DOI: 10.1177/1947601910365896.Peer-Reviewed Original ResearchCitationsAltmetricConceptsUp-regulated proteinsCytoskeletal proteinsBreast cancer tissuesMembrane traffic proteinsLabel-free quantitative proteomic analysisGene ontology molecular functionAcid metabolismHormone-dependent natureLabel-free quantitative proteomicsQuantitative proteomic analysisBreast tumorsCancer tissuesTargets of therapeutic drugsGene expression analysisAmino acid metabolismBreast cancerFatty acid metabolismReceptor tyrosine kinasesTrafficking proteinsProtein complementProtein expression profilesMolecular functionsIntervention of breast cancerSignaling proteinsUnique proteins
2006
Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues
Hwang S, Thumar J, Lundgren D, Rezaul K, Mayya V, Wu L, Eng J, Wright M, Han D. Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues. Oncogene 2006, 26: 65-76. PMID: 16799640, DOI: 10.1038/sj.onc.1209755.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsMultiple cancer typesShotgun methodTreatment of multiple cancer typesCancer tissuesCancerous prostate cellsStages of prostate carcinogenesisCancer typesFormalin-fixed paraffin-embedded archival tissuesParaffin-embedded archival tissueProstate cancer tissue samplesBioinformatics analysisMetabolic pathwaysProstate-specific antigenUpregulated proteinsCancer tissue samplesProteinDTP methodQuantification of prostate-specific antigenProstate carcinogenesisProstate cellsAbsolute quantification methodWnt-3Biopsy sectionsArchival tissueEarly detection
News
Copy Link
Get In Touch
Copy Link